Better options for treating lymphatic filariasis and other infections in communities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, interventional study evaluating mass drug administration in communities where lymphatic filariasis, scabies, and strongyloidiasis are common. Participants receive three single doses of either MoxDA or IDA, each spaced about a year apart, and are monitored for safety after each treatment. Researchers test participants for the targeted infections at enrollment and follow up with safety checks in the week after each dose. The study compares infection clearance and safety between the MoxDA and IDA regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated informed consent.
2. Resident in one of the study locations.

Exclusion Criteria:

There are no exclusion criteria to participation in the study.

Treatment Exclusion Criteria:

Participants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria:

1. Severe illness (any illness that is severe enough to interfere with activities of daily living);
2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole;
3. Pregnant;
4. Breastfeeding a baby within 7 days of birth;
5. Age \< 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or
6. Age \< 2 years or weight \< 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).

Where it's running

• Ministry of Health and Medical Services Fiji
  Suva, Fiji Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Expanding Access to Preventive Chemotherapy for Mobile and Migrant Communities

  This project tests whether a modified mass drug administration approach can reach mobile and migrant groups in Nigeria to reduce infections from river blindness, schistosomiasis, intestinal worms, and lymphatic filariasis.

  Recruiting Akwa Ibom State University, Ikot Akpaden, Nigeria · Ondo, Ondo, Taraba and Akwa Ibom · NCT07707817

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Moxidectin versus ivermectin mass treatment to control river blindness and other common infections in Angolan villages

  This project will test whether giving moxidectin or ivermectin to whole villages better lowers river blindness and other common infections in people living in selected Angolan communities.

  Recruiting Phase 4 Kirby Institute · Andulo, Bíe Province · NCT07145736

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.